Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke

Stroke

Volumn 36, Issue 11, 2005, Pages 2497-2499

  Smith, Eric E ^a   Abdullah, Abdul R ^a   Petkovska, Iva ^b   Rosenthal, Eric ^c   Koroshetz, Walter J ^a   Schwamm, Lee H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Angiography; Computed tomography; Outcome; Stroke, acute; Tissue plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; DEATH; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; FEMALE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGICAL COMPLICATION; PRIORITY JOURNAL; RANKIN SCALE; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

AGED; ANGIOGRAPHY; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; ISCHEMIA; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 27644586324     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000185798.78817.f3     Document Type: Article

References (9)

1. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility. Neurology. 2001;56:1015-1020.
2. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neural 2004;61:346-350.
3. Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, Alwell K, Gebel J, Szaflarski J, Pancioli A, Jauch E, Moomaw C, Shukla R, Broderick JP. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke. 2004;35:e27-e29.
4. Cocho D, Belvis R, Marti-Fabregas J, Molina-Porcel L, Diaz-Manera J, Aleu A, Pagonabarraga J, Garcia-Bargo D, Mauri A, Marti-Vilalta J-L. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology. 2005;64:719-720.
5. The NINDS rt-PA stroke study group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
6. Grotta JC, Welch KM, Pagan SC, Lu M, Frankel MR, Brott T, Levine SR, Lyden PD. Clinical deterioration following improvement in the NINDS rt-pa stroke trial. Stroke. 2001;32:661-668.
7. Adams HP, Bendixen BH, Rappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
8. Johnston SC, Leira EC, Hansen MD, Adams HP Jr. Early recovery after cerebral ischemia risk of subsequent neurological deterioration. Ann Neurol. 2003;54:439-444.
9. Johnston SC, Easton JD. Are patients with acutely recovered cerebral ischemia more unstable? Stroke. 2003;34:2446-2450.